NYSEAMERICAN:BPMX Biopharmx (BPMX) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free BPMX Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume336,508 shsAverage Volume2.15 million shsMarket Capitalization$111.86 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biopharmx alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Biopharmx Stock (NYSEAMERICAN:BPMX)BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC). Its clinical-stage product candidates include BPX01, a topical antibiotic gel that has completed Phase II clinical trials for the treatment of inflammatory lesions of acne; BPX04, a topical antibiotic, which is in pre-Phase II feasibility study for the treatment of inflammatory lesions of rosacea; BPX02, a development stage product candidate for aesthetic dermatology applications; and BPX03, a molecular iodine tablet, which has completed pre-Phase III clinical trial for the treatment of periodic breast pain associated with FBC and cyclic mastalgia. The company serves pharmaceutical companies; physician's practices, including obstetricians and gynecologists, dermatologists, and general practitioners; and retail customers through retail sales channels and/or pharmacy outlets. It has collaboration and license agreement with Iogen LLC to develop molecular iodine formulations; and collaboration and supply agreement with NuTech Medical, Inc. to develop products in the field of dermatology. The company is headquartered in Menlo Park, California.Read More Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. BPMX Stock News HeadlinesApril 20, 2024 | seekingalpha.comTMBRQ Trex Wind-down, Inc.April 18, 2024 | investing.comTrex Wind Down Inc (TMBRQ)April 26, 2024 | DTI (Ad)What is the 72-Hour Profit Surge?One of the most overlooked opportunities in the stock market is the 72-Hour Profit Surge... A short period of time where we can bet on a stock that is ALREADY “winning.” Let me give you a perfect example of how the Surge worked with Ross Stores. Back on November 16th, a little move was made that sent their stock soaring… The next day, my system would have alerted me that Ross Stores had entered the 72-Hour Profit Surge…July 8, 2023 | thestreet.comBioPharmX (BPMX) Stock Soars on Potential 'Breakthrough' Acne TreatmentOctober 3, 2022 | streetinsider.comForm 424B5 Timber Pharmaceuticals, - StreetInsider.comSeptember 22, 2022 | finance.yahoo.comOutlook on the Acne Treatment Global Market, to 2027 - Rising Public Knowledge of Cosmetic Acne Treatments is Driving Growth - Yahoo FinanceJuly 19, 2022 | globenewswire.comGlobal Acne Treatment Market, By Therapeutic Class, By Formulation, By Type, By Acne Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2027 - GlobeNewswireJuly 17, 2022 | seekingalpha.comTimber Pharmaceuticals, Inc. (TMBR) Stock Price Today, Quote & News - Seeking AlphaApril 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.July 14, 2022 | streetinsider.comForm DEF 14A Vivos Therapeutics, Inc. For: Jul 14 - StreetInsider.comMay 13, 2022 | marketscreener.comManagement's Discussion and Analysis of the Results of Operations - Marketscreener.comMarch 31, 2022 | globenewswire.comTimber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2021 Financial Results - GlobeNewswireMarch 31, 2022 | marketscreener.comTIMBER PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comMarch 16, 2022 | finance.yahoo.comAcne Drugs Global Market Report 2022 - Yahoo FinanceDecember 23, 2021 | benzinga.com2021 Metabolic Partnering Global Report - In-depth Understanding of Metabolic Deal Trends Since 2014 - Be - BenzingaDecember 15, 2021 | globenewswire.comAramis Biosciences Launches to Address Unmet Needs in Ocular Immunology - GlobeNewswireNovember 16, 2021 | streetinsider.comForm 10-Q Timber Pharmaceuticals, For: Sep 30 - StreetInsider.comNovember 16, 2021 | marketscreener.comTimber Pharmaceuticals : Provides Business Update and Announces Third Quarter 2021 Financial Results - Form 8-K - marketscreener.comOctober 13, 2021 | streetinsider.comVenus Concept Appoints Ross J. Portaro as President of Global Sales - StreetInsider.comOctober 13, 2021 | streetinsider.comForm 8-K Venus Concept Inc. For: Oct 05 - StreetInsider.comOctober 12, 2021 | gurufocus.comVenus Concept Appoints Ross J. Portaro as President of Global Sales - GuruFocus.comOctober 11, 2021 | globenewswire.comAcne Vulgaris Pipeline: Therapeutic Assessment, Emerging Drugs, Key Pharma Players, Clinical Trials, and Growth Prospects Analysis - GlobeNewswireAugust 31, 2021 | streetinsider.comForm PRER14A NEXTGEN HEALTHCARE, INC. - StreetInsider.comAugust 23, 2021 | streetinsider.comForm PRE 14A NEXTGEN HEALTHCARE, INC. For: Oct 13 - StreetInsider.comAugust 10, 2021 | globenewswire.comTimber Pharmaceuticals Provides Business Update and Announces Second Quarter 2021 Financial Results - GlobeNewswireJuly 22, 2021 | streetinsider.comGelteq Appoints Seasoned Pharma and Tech Executive, James Pekarsky, as Chief Financial Officer - StreetInsider.comSee More Headlines Receive BPMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biopharmx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/10/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:BPMX Previous SymbolNYSE:BPMX CUSIPN/A CIKN/A Webwww.biopharmx.com Phone+1-650-8895020FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares18,278,000Free FloatN/AMarket Cap$111.86 million OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. David S. Tierney M.D. (Age 55)Pres, CEO, CFO and Director Dr. Kin Foong Chan (Age 45)Exec. VP of Research & Technology Dr. José ZayasSr. VP of OperationsMs. Joyce Goto (Age 45)VP, Chief Accounting Officer & Controller Ms. AnnaMarie DanielsExec. VP of Clinical & Regulatory AffairsKey CompetitorsKinnate BiopharmaNASDAQ:KNTENGM BiopharmaceuticalsNASDAQ:NGMNervGen PharmaOTCMKTS:NGENFAmpliphi BiosciencesNYSEAMERICAN:APHBCybinOTCMKTS:CYBNView All Competitors BPMX Stock Analysis - Frequently Asked Questions How were Biopharmx's earnings last quarter? Biopharmx Corp (NYSEAMERICAN:BPMX) issued its quarterly earnings data on Tuesday, December, 10th. The biotechnology company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.64) by $0.96. When did Biopharmx's stock split? Shares of Biopharmx reverse split on Tuesday, May 19th 2020. The 1-12 reverse split was announced on Friday, May 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What other stocks do shareholders of Biopharmx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biopharmx investors own include Sarepta Therapeutics (SRPT), Netlist (NLST), Neovasc (NVCN), Hawkins (HWKN), Novavax (NVAX), LadRx (CYTR), Synergy Pharmaceuticals (SGYP), AVEO Pharmaceuticals (AVEO) and Rexahn Pharmaceuticals (REXN). How do I buy shares of Biopharmx? Shares of BPMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:BPMX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biopharmx Corp Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
